2025-10-14 - Analysis Report
Okay, here's a report analyzing TransMedics Group Inc. (TMDX) based on the data you provided:

## TransMedics Group Inc. (TMDX) Analysis

**Company Overview:** TransMedics Group Inc. is a medical technology company focused on developing and delivering innovative organ preservation systems for transplant therapy.

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return (TMDX):** 179.81%
*   **Cumulative Return (VOO):** 71.92%
*   **Absolute Spread:** 97.1
*   **Relative Spread:** 53.3 (Indicates TMDX's performance is in the upper range of its historical outperformance relative to VOO.)

**Analysis:** TMDX has significantly outperformed the S&P 500 (VOO) over the period examined. The relative spread suggests this outperformance is substantial compared to its historical range.

**Alpha, Beta Analysis**

| Year        | CAGR     | MDD   | Alpha   | Beta | Cap(B) |
| ----------- | -------- | ----- | ------- | ---- | ------ |
| 2019-2021   | -18.0%  | 83.5% | -61.0% | -0.0 | 0.7    |
| 2020-2022   | 94.0%   | 83.5% | 95.0% | 0.0  | 2.1    |
| 2021-2023   | 65.0%   | 80.5% | 64.0% | 0.1  | 2.7    |
| 2022-2024   | 130.0%  | 85.5% | 109.0% | 0.1  | 2.1    |
| 2023-2025   | 101.0%  | 85.5% | 39.0% | 0.3  | 3.8    |

*   **CAGR:** Shows strong growth potential, especially in recent periods (2020-2025).
*   **MDD:** Indicates significant volatility and downside risk.
*   **Alpha:** Consistently positive, indicating outperformance compared to the benchmark.
*   **Beta:** Relatively low, suggesting lower sensitivity to market movements.
*   **Cap:** Increasing capitalization, implying expanding company size.

### 2. Recent Price Action

*   **Current Price:** 111.71
*   **Previous Close:** 107.29
*   **Change:** 4.12
*   **5-day Moving Average:** 112.12
*   **20-day Moving Average:** 115.78
*   **60-day Moving Average:** 115.63

**Analysis:** The stock price has recently increased (change of 4.12). However, the current price is below the 5-day, 20-day, and 60-day moving averages, suggesting a possible short-term downtrend or consolidation. The recent price increase could signal a potential reversal.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 41.65 (Neutral, neither overbought nor oversold)
*   **PPO:** -0.53 (Slightly bearish, indicating potential weakness in momentum)
*   **Hybrid Signal:** Buy 100% of cash (Very Safe)
*   **Recent (20-day) Relative Divergence Change:** -6.2 (Short-term decline)
*   **Expected Return:** 63.0% (Significant potential outperformance vs. S&P 500 over the long term)

**Analysis:** The MRI suggests a medium level of investment risk.  The RSI is neutral. The negative PPO and declining relative divergence suggest some short-term bearish momentum. Despite the technical caution, the hybrid signal recommends buying. The substantial expected return indicates confidence in long-term growth. The significant price change from the previous close indicates volatility and recent positive market reaction.

### 4. Recent News & Events

*   **Positive Analyst Coverage:** Jefferies initiated coverage with a "Buy" rating and a $145 price target.
*   **Growth & Value Recognition:** Articles highlight TransMedics' growth in returns on capital, strong growth potential, and potential undervaluation.
*   **Innovation & Partnerships:** News of organ transport partnerships (Mercedes-Benz) highlights innovation and market expansion.

**Analysis:** Recent news is overwhelmingly positive, with analyst upgrades, recognition of strong growth, and innovative partnerships. This news likely contributed to the recent price increase.

### 4-2) Analyst Opinions

*   **Consensus:** Buy
*   **Mean Rating:** 1.82 (~Buy)
*   **Target Price:** 141.10 (Suggests significant upside potential)

**Analysis:** Analyst consensus is strongly bullish on TMDX, with a mean rating indicating a "Buy" recommendation and a target price significantly higher than the current price.

### 5. Recent Earnings Analysis

| Date       | EPS   | Expected EPS |
| ---------- | ----- | ------------ |
| 2025-07-30 | 0.92  | 0.48         |
| 2025-05-08 | 0.70  | 0.29         |
| 2025-02-27 | 0.19  | 0.22         |
| 2024-10-28 | 0.12  | 0.29         |
| 2024-07-31 | 0.35  | 0.21         |

**Analysis:** TransMedics has consistently beaten EPS expectations in recent quarters (except for 2024-10-28), indicating strong financial performance and potential for continued growth.

### 6. Financial Information

| Quarter    | Revenue   | Profit Margin |
| ---------- | --------- | ------------- |
| 2025-06-30 | $0.16B    | 61.38%        |
| 2025-03-31 | $0.14B    | 61.47%        |
| 2024-12-31 | $0.12B    | 59.21%        |
| 2024-09-30 | $0.11B    | 55.94%        |
| 2024-06-30 | $0.11B    | 60.59%        |

| Quarter    | Equity    | ROE       |
| ---------- | --------- | --------- |
| 2025-06-30 | $0.32B    | 10.97%    |
| 2025-03-31 | $0.27B    | 9.64%     |
| 2024-12-31 | $0.23B    | 3.00%     |
| 2024-09-30 | $0.21B    | 2.01%     |
| 2024-06-30 | $0.19B    | 6.42%     |

**Analysis:** Revenue, profit margins, equity, and ROE have shown strong growth, indicating improving financial health and efficient capital utilization.

### 7. Overall Summary

TransMedics Group Inc. (TMDX) presents a compelling investment case based on the data provided. The company has significantly outperformed the S&P 500, demonstrating strong growth potential and positive financial trends. Recent news and analyst ratings are overwhelmingly positive, supporting the bullish outlook.

**Key Positives:**

*   **Strong Outperformance:** Substantially higher returns compared to the S&P 500.
*   **Positive Growth Trajectory:** Increasing revenue, profit margins, equity, and ROE.
*   **Consistent Earnings Beats:** Exceeding EPS expectations in recent quarters.
*   **Positive Analyst Sentiment:** "Buy" consensus and significant upside potential based on target prices.
*   **Innovative & Expanding:** Partnerships and growing market presence.
*   **High Expected Return:** A significant potential for long-term outperformance.

**Potential Risks:**

*   **High Volatility:** Evidenced by the MDD and recent price fluctuations.
*   **Short-Term Bearish Momentum:** Indicated by the PPO and recent relative divergence decline.

**Overall Recommendation:**

While short-term caution may be warranted due to technical indicators, the overall outlook for TMDX is positive. The company's strong financial performance, growth potential, positive news flow, and analyst support suggest that it could be a worthwhile long-term investment. Consider Dollar-Cost Averaging, dividing the total sum of money to be invested into equal increments to buy the asset over time, to mitigate the risk of volatility and short-term price fluctuations.
